Rein Therapeutics Inc <RNTX.OQ> expected to post a loss of 22 cents a share - Earnings Preview

• Rein Therapeutics Inc RNTX.OQ RNTX.O is expected to show no change in quarterly revenue when it reports results on August 12 (estimated) for the period ending June 30 2025

• ​LSEG's mean analyst estimate for Rein Therapeutics Inc is for a loss of 22 cents per share.

• The one available analyst rating on the shares is "buy".

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Rein Therapeutics Inc is $7.00, about 84.1% above its last closing price of $1.11

This summary was machine generated August 8 at 23:05 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)